Earnings analysis · 10-Q
RVMD earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Revolution Medicines reported disappointing financial results for Q1 2026, with no revenue and an EPS loss of -2.29, missing consensus estimates of -1.84. The company incurred significant operational expenses, including…
Read full summary
Revolution Medicines reported disappointing financial results for Q1 2026, with no revenue and an EPS loss of -2.29, missing consensus estimates of -1.84. The company incurred significant operational expenses, including $344 million in R&D costs, which pressure cash reserves to $1.9 billion, aligning with anticipated higher operating costs as guidance was updated to $1.7-1.8 billion for 2026. Significant risks remain in ongoing clinical developments and the broader market competition.
Reported figures
- Earnings per share
- $-2.29
What stood out
-
Q1 2026 EPS and Revenue Miss
Reported EPS of -2.29 and revenue of $0, missing estimates of -1.84 and $6.1M.
-
Massive R&D Spending
R&D expenses reached $344 million in Q1 2026, significantly up from $206 million a year prior.
-
Cash Reserves Total $1.9 Billion
Cash, cash equivalents, and marketable securities fell from $2.0 billion at the end of 2025.
-
Increased Operational Spend Guidance
GAAP operating expenses guidance for 2026 was updated to $1.7 to $1.8 billion.
What to watch
-
$453.8M Net Loss in Q1 2026
The company incurred a net loss of $453.8 million for the quarter, significantly impacting liquidity.
-
Cash Position Declining
Decline in cash reserves to $1.9 billion raises concerns about future funding for operations.
-
Challenging Regulatory Environment Ahead
The uncertainty in FDA approvals and the recent focus on drug pricing reforms could affect market operations.
Management's outlook
2026 GAAP operating expenses guidance updated to a range of $1.7 to $1.8 billion.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.